Accord Rolls Out Zercepac Trastuzumab Biosimilar In UK
Rival To Herceptin Was Developed By China’s Shanghai Henlius Biotech
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
